Our findings are in concordance with other reports that demonstrate a dependence on AKT and mTOR signaling in T-ALL, but this study suggests that targeting AKT or mTOR in NOTCH-mutant T-ALL would be advantageous over PI3K inhibitors [33–37]. Here, PIK3CA is linked to acute lymphoblastic leukemia.